Suchergebnisse

One Cells and Development -- 1 Innervation of teeth: developmental aspects -- 2 Odontoblasts: developmental aspects -- 3 Dental pulp fibroblasts in culture -- 4 Concluding remarks -- Two Anatomical Aspects of the Pulp — Odontoblast and Vascular Architecture -- 5 Role of the odontoblast process -- 6 Change of vascular architecture of dental pulp with growth -- 7 Concluding remarks -- Three Physiological Aspects of the Pulp — Microcirculatory and Sensory Functions -- 8 Intradental sensory units -- 9 Microcirculation: function and regulation in microvasculature -- 10 Haemodynamic regulation of the dental pulp -- 11 Interstitial fluid pressure and transmicrovascular fluid flow -- 12 Concluding remarks -- Four Biochemical Aspects of the Pulp — Enzymes and Matrix -- 13 Enzymes of the glycolytic pathway-phosphofructokinase, pyruvate kinase and lactate dehydrogenase -- 14 Collagenase synthesis by odontoblast-like cells (RP cells) preparation of monoclonal antibodies against RP cell collagenase and characterization of the enzyme -- 15 Dental pulp matrix — collagens and glycoproteins -- 16 Glycosaminoglycans in dental pulp -- 17 Concluding remarks -- Five Neuroregulators — Classic Neurotransmitters -- 18 The adrenergic system and dental pulp -- 19 The cholinergic system and the dental pulp -- 20 Concluding remarks -- Six Neuroregulators — Neuropeptides -- 21 Distribution of peptidergic nerves -- 22 Functions of peptidergic nerves -- 23 Concluding remarks -- Seven Bioactive Substances -- 24 Neurotrophic substances -- 25 Bradykinin and enkephalins -- 26 Prostaglandins and leukotrienes in dental pulp: their possible roles in pulp pathophysiology -- 27 Concluding remarks -- Eight Pathological Aspects of the Pulp and Medication -- 28 Reactions of dental sensory innervation to injury and inflammation -- 29 Proteases in inflammation -- 30 Arachidonic acid metabolism and antiseptics -- 31 Concluding Remarks.

Abstract
According to the World Health Organization (WHO), viral diseases continue to rise, and pose a significant public health problem. Novel coronavirus disease (COVID-19) is an infectious disease caused by SARS-CoV-2. The pathogenesis and clinical manifestations of COVID-19 is close to Amraz-e-Wabai (epidemic diseases) which was described by Hippocrates, Galen, Aristotle, Razes, Haly Abbas, Avicenna, Jurjani etc. Presently, there is no specific or challenging treatment available for COVID-19. Renowned Unani Scholars recommended during epidemic situation to stay at home, and fumigate the shelters with aromatics herbs like Ood kham (Aquilaria agallocha Roxb.), Kundur (Boswellia serrata Roxb), Kafoor (Cinnamomum camphora L.), Sandal (Santalum album L), Hing (Ferula foetida L.) etc. Use of specific Unani formulations are claimed effective for the management of such epidemic or pandemic situation like antidotes (Tiryaqe Wabai, Tiryaqe Arba, Tiryaqe Azam, Gile Armani), Herbal Decoction (Joshandah), along with Sharbate Khaksi, Habbe Bukhar, Sharbate Zanjabeel, Khamira Marwareed, Jawarish Jalinus, and Sirka (vinegar). Such drugs are claimed for use as antioxidant, immunomodulatory, cardiotonic, and general tonic actions. The study enumerates the literature regarding management of epidemics in Unani medicine and attempts to look the same in the perspective of COVID-19 prevention and management.

This review covers the last 20 years of UK drug control policy leading up to the recent Psychoactive Substances Act. It explores policy decision made in relation to MDMA and mephedrone that not only were associated with increased drug harms overall but also had a significant detrimental effect on the UK research base. The new UK legislation on synthetic cannabinoids and other novel psychoactive substances threatens to do the same, showing that there is still much to learn from the decisions of the past. In future input from academic societies such as the BPS could help improve policy evaluation and policy development and so help avoid such problems in the future.

Cover -- Title page -- Copyright page -- Dedication -- Contents -- List of Contributors -- Preface -- I - Setting the scene, botanical, general and international aspects -- Chapter 1 - The Cannabis Plant: Botanical Aspects -- List of Abbreviations -- Introduction -- Botany of Cannabis -- Macroscopical Features -- Microscopical Features -- Classification of Cannabis -- Other Recent Taxonomic Studies -- Chemotaxonomic Classification -- Molecular Classification -- Current Cannabis Varieties -- Genetics of Cannabis -- Genome of Cannabis sativa -- Geographical Distribution -- Agricultural Status -- Conservation Initiatives -- Ex Situ Conservation in Gene Banks -- In Situ Conservation as In Vitro Gene Banks -- Cultivation Techniques of Cannabis -- Outdoor Cultivation -- Indoor Cultivation -- In vitro Micropropagation -- Recommendations for Future Action -- Mini-Dictionary -- References -- Chapter 2 - The Biosynthesis of Cannabinoids -- List of Abbreviations -- Introduction -- Cannabinoid precursor biosynthesis -- Polyketide Pathway Toward Olivetolic Acid -- Biosynthesis of Geranyl Diphosphate -- Cannabigerolic Acid Biosynthesis -- Cannabinoid pathway -- Tetrahydrocannabinolic Acid Synthase -- Cannabidiolic Acid Synthase -- Cannabichromenic Acid Synthase (CBCAS) -- Cannabinoids with Propyl Side Chains -- Mini-dictionary -- Acknowledgment -- References -- Chapter 3 - Increasing Plant Concentrations of THC and Implications on Health Related Disorders -- List of Abbreviations -- Introduction -- Cannabis plants: has the potency changed? -- Does higher cannabis potency lead to increased exposure to THC? -- Higher-Potency Cannabis and Plasma THC Levels -- Titration of THC Intake During Smoking -- THC Concentrations in Biological Samples -- Does higher exposure to THC increase the risk of adverse health effects?.